Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.60 |
| ▸ | LMNA | P02545 | 8/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | MEN1 | O00255 | 6/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 5/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | CCR6 | P51684 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8238479 | 0.79 | MAPT (0.61) | MAPTLMNAKMT2AMEN1NPSR1 | |
| SCHEMBL23345459 | 0.78 | KMT2A (0.72) | MAPTLMNAKMT2AMEN1NPSR1 | |
| SCHEMBL23345473 | 0.76 | MAPT (0.71) | MAPTLMNAKMT2AMEN1NPSR1 | |
| SCHEMBL23345514 | 0.76 | MAPT (0.71) | MAPTLMNAKMT2AMEN1NPSR1 | |
| SCHEMBL13091221 | 0.76 | MAPT (0.60) | MAPTLMNAKMT2AMEN1NPSR1 | |
| SCHEMBL23345481 | 0.76 | KMT2A (0.70) | MAPTLMNAKMT2AMEN1NPSR1 | |
| SCHEMBL23326606 | 0.75 | MAPT (1.00) | MAPTLMNAKMT2AMEN1NPSR1 | |
| SCHEMBL23345457 | 0.75 | MAPT (1.00) | MAPTLMNAKMT2AMEN1NPSR1 | |
| SCHEMBL23326605 | 0.75 | MAPT (1.00) | MAPTLMNAKMT2AMEN1NPSR1 | |
| SCHEMBL23345489 | 0.75 | MAPT (0.65) | MAPTLMNAKMT2AMEN1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9687491-B1 | Compositions and methods of targeting mutant K-Ras | NANTBIOSCIENCE, INC. (US) | 2017-06-27 | — | — | US | claimed |
| US-10668076-B1 | Compositions and methods of targeting mutant K-Ras | NANTBIO, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-9687491-B1 | Compositions and methods of targeting mutant K-Ras | NANTBIOSCIENCE, INC. (US) | 2017-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10668076-B1 | Compositions and methods of targeting mutant K-Ras | KRAS, NRAS, HRAS | MAPT 3827/4885LMNA 3133/4885KMT2A 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.